Nonetheless, collaboration with established local companies will help manufacturers to provide effective services and, at the same time, maintain profit margins. Integration of continuous glucose monitors with insulin pumps will pave way for reimbursement options for manufactures, thus reducing the total cost incurred by patients.

"To enable the market participants to include such systems in the reimbursable category, significant clinical evidence suggesting that the device is essential for the patient's well-being is required," concludes Joshi. "Moreover, when CGM is integrated with insulin pumps, the product will become reimbursable as it is likely to fall under the medically essential classification of insurance agencies."

European Market for Continuous Glucose Monitoring is part of the Patient Monitoring Growth Partnership Services programme, which also includes research in the following markets: European Market for Ventilation and Airway Management Devices, European Markets for Disease Management, European Telemetry Equipment Market, and European Market for Multiparameter midrange Patient Monitors. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

SOURCE Frost & Sullivan